Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 182,412,384
  • Shares Outstanding, K 2,757,140
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 5,691 M
  • 36-Month Beta 0.79
  • Price/Sales 4.56
  • Price/Cash Flow 11.10
  • Price/Book 4.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.54 +9.28%
on 01/26/17
66.16 unch
on 02/24/17
+4.95 (+8.09%)
since 01/24/17
3-Month
58.56 +12.98%
on 12/30/16
66.16 unch
on 02/24/17
+4.52 (+7.33%)
since 11/23/16
52-Week
50.09 +32.08%
on 03/01/16
66.16 unch
on 02/24/17
+15.60 (+30.85%)
since 02/24/16

Most Recent Stories

More News
Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen

Not intended for U.S. and UK based media

MRK : 66.16 (+0.47%)
Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen

DARMSTADT, Germany, February 24, 2017 /PRNewswire/ --

MRK : 66.16 (+0.47%)
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

AZN : 29.35 (-0.54%)
MRK : 66.16 (+0.47%)
LLY : 82.87 (+0.39%)
NVS : 77.28 (-0.22%)
PFE : 34.26 (+0.59%)
GSK : 41.56 (+0.17%)
BMY : 56.44 (+1.20%)
Bristol Myers' Future Unsure as Carl Icahn Takes Stake

Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?

MRK : 66.16 (+0.47%)
BMY : 56.44 (+1.20%)
Ontario and British Columbia expand treatment access to chronic hepatitis C (CHC) patients

An estimated 185,000 people in Ontario and British Columbia have hepatitis C, a chronic liver disease that, if left untreated, can lead to cirrhosis, liver cancer and liver transplants.(2) Merck Canada...

MRK : 66.16 (+0.47%)
Can Carl Icahn Save Bristol Myers Squibb?

Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

MRK : 66.16 (+0.47%)
BMY : 56.44 (+1.20%)
STEER & Merck in Partnership for Collaborative Research on Processing Special Effect Pigments

Scientists From Two Companies to Accelerate Development of Appropriate Technology for Adoption by Plastic Industry

MRK : 66.16 (+0.47%)
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

AZN : 29.35 (-0.54%)
MRK : 66.16 (+0.47%)
JNJ : 122.73 (+0.85%)
AGN : 245.37 (-0.67%)
VRX : 16.18 (-2.41%)
STEER & Merck in Partnership for Collaborative Research on Processing Special Effect Pigments

BANGALORE, February 21, 2017 /PRNewswire/ --

MRK : 66.16 (+0.47%)
The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta

The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta

PNC : 126.88 (-0.98%)
ESRX : 71.55 (+0.87%)
MRK : 66.16 (+0.47%)
VRSN : 83.31 (+1.10%)
MLM : 210.05 (+0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 66.51
1st Resistance Point 66.34
Last Price 66.16
1st Support Level 65.81
2nd Support Level 65.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.